<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03342157</url>
  </required_header>
  <id_info>
    <org_study_id>17.120</org_study_id>
    <nct_id>NCT03342157</nct_id>
  </id_info>
  <brief_title>Docusate/Senna for the Treatment of Diabetic Gastroparesis</brief_title>
  <official_title>Pilot Study for the Efficacy and Tolerability of Senokot-S in the Treatment of Diabetic Gastroparesis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aurora Health Care</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aurora Health Care</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to evaluate the efficacy of the stimulant laxative Senokot-SÂ® for the
      treatment of diabetic gastroparesis. Senokot-S, and its metabolites, are thought to produce
      peristalsis, drive intraluminal fluid and electrolyte shifts, and have an irritant effect on
      the gut mucosa. These complex physiologic mechanisms appear may sufficiently promote stomach
      emp-tying, and thereby reduce or eliminate the severity of gastroparesis symptoms. In this
      open label study, participants will be randomized into high and low dose groups to assess for
      ideal dosing and tolerability. It is the overall goal of this study to select the most
      promising dose-strength for the treatment of mild through severe gastroparesis.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 2, 2018</start_date>
  <completion_date type="Anticipated">January 25, 2019</completion_date>
  <primary_completion_date type="Anticipated">January 25, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Modified Gastroparesis Cardinal Symptom Index-Daily Diary (mGCSI-DD)</measure>
    <time_frame>28 days</time_frame>
    <description>mGCSI-DD uses 6-point Likert scale from 0 (none) to very severe (5)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency of use of breakthrough medication</measure>
    <time_frame>28 days</time_frame>
    <description>Change in the frequency of use of breakthrough medication - daily diary</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of bowel movements</measure>
    <time_frame>28 days</time_frame>
    <description>Change in the frequency of bowel movements - daily diary</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Diabetic Gastroparesis</condition>
  <arm_group>
    <arm_group_label>High-dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>8.6/50 mg of senna/docusate, oral, twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low-dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>8.6/50 mg of senna/docusate, oral, once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>senna/docusate</intervention_name>
    <description>Stimulant laxative</description>
    <arm_group_label>High-dose</arm_group_label>
    <arm_group_label>Low-dose</arm_group_label>
    <other_name>Senokot-S</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18-75 years, male and non-pregnant, non-lactating females

          -  Diagnosis of type 1 or type 2 diabetes mellitus

          -  Clinical diagnosis of diabetic gastroparesis

        Exclusion Criteria:

          -  Diagnosed idiopathic gastroparesis

          -  A history or inflammatory bowel disease, such as Crohn's disease or ulcerative colitis

          -  A history of bowel obstruction, current unexplained abdominal pain, or undiagnosed
             rectal bleeding

          -  Gastrointestinal cancer

          -  Any active cancer

          -  Prior gastric surgery

          -  End-stage heart disease, liver disease, lung disease

          -  Known or suspected drug abuse

          -  Any condition requiring use of daily narcotics

          -  Concurrent usage of mineral oil or products containing mineral oil

          -  Current or recent (within the last 3 months) usage of Senokot-S, docusate or senna
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bradley Gose, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Aurora Health Care</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gary Dennison, CIP</last_name>
    <phone>414-385-1913</phone>
    <email>gary.dennison@aurora.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Carol Tutino, RN,MS,CCRC</last_name>
    <phone>414-649-5526</phone>
    <email>carol.tutino@aurora.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Aurora Health Care</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lynda Yanny</last_name>
      <phone>414-649-6685</phone>
      <email>lynda.yanny@aurora.org</email>
    </contact>
    <investigator>
      <last_name>Bradley Gose, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 10, 2017</study_first_submitted>
  <study_first_submitted_qc>November 10, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 14, 2017</study_first_posted>
  <last_update_submitted>April 3, 2018</last_update_submitted>
  <last_update_submitted_qc>April 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 4, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastroparesis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sennoside A&amp;B</mesh_term>
    <mesh_term>Bismuth subsalicylate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

